Catalyst Event
Natera Inc (NTRA) · Earnings Release
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
5/7/2026, 12:00:00 AM
Natera reported Q1 2026 financial results. Revenue of $696.6 million beat analyst expectations, but EPS of -$0.60 missed forecasts. The company raised its full-year 2026 revenue guidance. The stock fell 9.69% in after-hours trading following the announcement.
Korean Translation
Natera, 2026년 1분기 실적 발표. 매출은 6억 9,660만 달러로 분석가 예상을 상회했으나, 주당순이익(EPS)은 -0.60달러로 예상치를 하회함. 회사는 2026년 연간 매출 가이던스를 상향 조정함. 발표 후 시간 외 거래에서 주가는 9.69% 하락함.
Related Recent Events
JD Health International Inc (6618) · Earnings Release
Low importance estimated as no market reaction has occurred yet; Q2 2026 earnings report scheduled.
8/12/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the final dividend of RMB 1.43 per 10 shares, scheduled to be paid on July 13, 2026. Low importance estimated as the dividend amount is within historical norms, scheduled.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date (2026-06-12) for the proposed 2025 final dividend of HK$0.169 per share is scheduled.
6/12/2026, 12:00:00 AM
Veracyte Inc (VCYT) · Other
Annual Meeting of Stockholders on 2026-06-10, with proposals including the election of directors and an expansion of the 2023 Equity Incentive Plan scheduled.
6/10/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Pacific Biosciences of California Inc (PACB) · Other
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, including a proposal to increase the number of shares reserved for the 2020 Equity Incentive Plan by 16,000,000. A low impact is estimated due to potential share dilution, scheduled.
6/3/2026, 12:00:00 AM